SBI Securities Co. Ltd. Takes Position in BioNTech SE (NASDAQ:BNTX)

SBI Securities Co. Ltd. bought a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,429 shares of the company's stock, valued at approximately $391,000.

Several other large investors have also added to or reduced their stakes in BNTX. First Trust Direct Indexing L.P. bought a new stake in shares of BioNTech during the 3rd quarter valued at $245,000. GSA Capital Partners LLP purchased a new stake in BioNTech in the 3rd quarter worth $373,000. Baillie Gifford & Co. raised its holdings in BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after acquiring an additional 31,773 shares during the period. Victory Capital Management Inc. purchased a new position in shares of BioNTech in the third quarter valued at about $345,000. Finally, Planning Capital Management Corp boosted its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after acquiring an additional 450 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research analyst reports. Canaccord Genuity Group raised their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a research note on Wednesday, November 27th. The Goldman Sachs Group upgraded BioNTech from a "neutral" rating to a "buy" rating and raised their price objective for the company from $90.00 to $137.00 in a research report on Friday, November 8th. HC Wainwright reiterated a "buy" rating and issued a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Berenberg Bank assumed coverage on BioNTech in a report on Tuesday, November 19th. They set a "buy" rating and a $130.00 price target for the company. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $142.72.

Remove Ads

BioNTech Trading Down 1.8 %

Shares of NASDAQ BNTX traded down $2.05 during midday trading on Friday, hitting $108.78. The company's stock had a trading volume of 1,364,276 shares, compared to its average volume of 781,154. The business's 50 day moving average is $117.01 and its two-hundred day moving average is $112.46. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $26.08 billion, a P/E ratio of -51.80 and a beta of 0.30.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.